Literature DB >> 21503265

Inhibition of the Hematopoietic Protein Tyrosine Phosphatase by Phenoxyacetic Acids.

Ekaterina V Bobkova1, Wallace H Liu, Sharon Colayco, Justin Rascon, Stefan Vasile, Carlton Gasior, David A Critton, Xochella Chan, Russell Dahl, Ying Su, Eduard Sergienko, Thomas D Y Chung, Tomas Mustelin, Rebecca Page, Lutz Tautz.   

Abstract

Protein tyrosine phosphatases (PTPs) have only recently become the focus of attention in the search for novel drug targets despite the fact that they play vital roles in numerous cellular processes and are implicated in many human diseases. The hematopoietic protein tyrosine phosphatase (HePTP) is often found dysregulated in preleukemic myelodysplastic syndrome (MDS), as well as in acute myelogenous leukemia (AML). Physiological substrates of HePTP include the mitogen-activated protein kinases (MAPKs) ERK1/2 and p38. Specific modulators of HePTP catalytic activity will be useful for elucidating mechanisms of MAPK regulation in hematopietic cells, and may also provide treatments for hematopoietic malignancies such as AML. Here we report the discovery of phenoxyacetic acids as inhibitors of HePTP. Structure-activity relationship (SAR) analysis and in silico docking studies reveal the molecular basis of HePTP inhibition by these compounds. We also show that these compounds are able to penetrate cell membranes and inhibit HePTP in human T lymphocytes.

Entities:  

Year:  2011        PMID: 21503265      PMCID: PMC3077561          DOI: 10.1021/ml100103p

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

1.  Design and synthesis of a dimeric derivative of RK-682 with increased inhibitory activity against VHR, a dual-specificity ERK phosphatase: implications for the molecular mechanism of the inhibition.

Authors:  T Usui; S Kojima; S Kidokoro; K Ueda; H Osada; M Sodeoka
Journal:  Chem Biol       Date:  2001-12

Review 2.  Structural and evolutionary relationships among protein tyrosine phosphatase domains.

Authors:  J N Andersen; O H Mortensen; G H Peters; P G Drake; L F Iversen; O H Olsen; P G Jansen; H S Andersen; N K Tonks; N P Møller
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

Review 3.  Protein tyrosine phosphatases and the immune response.

Authors:  Tomas Mustelin; Torkel Vang; Nunzio Bottini
Journal:  Nat Rev Immunol       Date:  2005-01       Impact factor: 53.106

Review 4.  Protein tyrosine phosphatases: from genes, to function, to disease.

Authors:  Nicholas K Tonks
Journal:  Nat Rev Mol Cell Biol       Date:  2006-11       Impact factor: 94.444

5.  Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTP).

Authors:  M Saxena; S Williams; J Brockdorff; J Gilman; T Mustelin
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

6.  Hematopoietic protein tyrosine phosphatase suppresses extracellular stimulus-regulated kinase activation.

Authors:  M Gronda; S Arab; B Iafrate; H Suzuki; B W Zanke
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

Review 7.  Targeting the PTPome in human disease.

Authors:  Lutz Tautz; Maurizio Pellecchia; Tomas Mustelin
Journal:  Expert Opin Ther Targets       Date:  2006-02       Impact factor: 6.902

8.  The protein tyrosine phosphatase HePTP regulates nuclear translocation of ERK2 and can modulate megakaryocytic differentiation of K562 cells.

Authors:  S M Pettiford; R Herbst
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

9.  Knowledge-based characterization of similarity relationships in the human protein-tyrosine phosphatase family for rational inhibitor design.

Authors:  Dusica Vidović; Stephan C Schürer
Journal:  J Med Chem       Date:  2009-11-12       Impact factor: 7.446

10.  Molecular cloning and chromosomal mapping of a human protein-tyrosine phosphatase LC-PTP.

Authors:  M Adachi; M Sekiya; M Isobe; Y Kumura; Z Ogita; Y Hinoda; K Imai; A Yachi
Journal:  Biochem Biophys Res Commun       Date:  1992-08-14       Impact factor: 3.575

View more
  5 in total

1.  Inhibition of hematopoietic protein tyrosine phosphatase augments and prolongs ERK1/2 and p38 activation.

Authors:  Eduard Sergienko; Jian Xu; Wallace H Liu; Russell Dahl; David A Critton; Ying Su; Brock T Brown; Xochella Chan; Li Yang; Ekaterina V Bobkova; Stefan Vasile; Hongbin Yuan; Justin Rascon; Sharon Colayco; Shyama Sidique; Nicholas D P Cosford; Thomas D Y Chung; Tomas Mustelin; Rebecca Page; Paul J Lombroso; Lutz Tautz
Journal:  ACS Chem Biol       Date:  2011-11-17       Impact factor: 5.100

Review 2.  Small molecule tools for functional interrogation of protein tyrosine phosphatases.

Authors:  Rongjun He; Li-Fan Zeng; Yantao He; Sheng Zhang; Zhong-Yin Zhang
Journal:  FEBS J       Date:  2012-08-16       Impact factor: 5.542

3.  High-throughput screening for protein tyrosine phosphatase activity modulators.

Authors:  Lutz Tautz; Eduard A Sergienko
Journal:  Methods Mol Biol       Date:  2013

4.  Dual-specificity phosphatase 3 deficiency or inhibition limits platelet activation and arterial thrombosis.

Authors:  Lucia Musumeci; Marijke J Kuijpers; Karen Gilio; Alexandre Hego; Emilie Théâtre; Lisbeth Maurissen; Maud Vandereyken; Catia V Diogo; Christelle Lecut; William Guilmain; Ekaterina V Bobkova; Johannes A Eble; Russell Dahl; Pierre Drion; Justin Rascon; Yalda Mostofi; Hongbin Yuan; Eduard Sergienko; Thomas D Y Chung; Marc Thiry; Yotis Senis; Michel Moutschen; Tomas Mustelin; Patrizio Lancellotti; Johan W M Heemskerk; Lutz Tautz; Cécile Oury; Souad Rahmouni
Journal:  Circulation       Date:  2014-12-17       Impact factor: 29.690

5.  A New Paradigm for KIM-PTP Drug Discovery: Identification of Allosteric Sites with Potential for Selective Inhibition Using Virtual Screening and LEI Analysis.

Authors:  James Adams; Benjamin P Thornton; Lydia Tabernero
Journal:  Int J Mol Sci       Date:  2021-11-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.